161 related articles for article (PubMed ID: 7764456)
1. Kinetic resistance to anticancer agents.
Dimanche-Boitrel MT; Garrido C; Chauffert B
Cytotechnology; 1993; 12(1-3):347-56. PubMed ID: 7764456
[TBL] [Abstract][Full Text] [Related]
2. Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells.
Dimanche-Boitrel MT; Pelletier H; Genne P; Petit JM; Le Grimellec C; Canal P; Ardiet C; Bastian G; Chauffert B
Int J Cancer; 1992 Mar; 50(5):677-82. PubMed ID: 1544702
[TBL] [Abstract][Full Text] [Related]
3. Circumvention of confluence-dependent resistance in a human multi-drug-resistant colon-cancer cell line.
Garrido C; Chauffert B; Pinard D; Tibaut F; Genne P; Assem M; Dimanche-Boitrel MT
Int J Cancer; 1995 Jun; 61(6):873-9. PubMed ID: 7790124
[TBL] [Abstract][Full Text] [Related]
4. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion.
Pelletier H; Millot JM; Chauffert B; Manfait M; Genne P; Martin F
Cancer Res; 1990 Oct; 50(20):6626-31. PubMed ID: 2208125
[TBL] [Abstract][Full Text] [Related]
6. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
7. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
Sullivan DM; Latham MD; Ross WE
Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
[TBL] [Abstract][Full Text] [Related]
8. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
[TBL] [Abstract][Full Text] [Related]
9. Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines.
Robson CN; Hoban PR; Harris AL; Hickson ID
Cancer Res; 1987 Mar; 47(6):1560-5. PubMed ID: 2434220
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
11. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light.
Ohga T; Koike K; Ono M; Makino Y; Itagaki Y; Tanimoto M; Kuwano M; Kohno K
Cancer Res; 1996 Sep; 56(18):4224-8. PubMed ID: 8797596
[TBL] [Abstract][Full Text] [Related]
12. Effects of four chemotherapeutic agents, bleomycin, etoposide, cisplatin, and cyclophosphamide, on DNA damage and telomeres in a mouse spermatogonial cell line.
Liu M; Hales BF; Robaire B
Biol Reprod; 2014 Apr; 90(4):72. PubMed ID: 24571982
[TBL] [Abstract][Full Text] [Related]
13. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).
Friedmann B; Caplin M; Hartley JA; Hochhauser D
Clin Cancer Res; 2004 Oct; 10(19):6476-86. PubMed ID: 15475435
[TBL] [Abstract][Full Text] [Related]
14. Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide.
Asano T; Zwelling LA; An T; McWatters A; Herzog CE; Mayes J; Loughlin SM; Kleinerman ES
Br J Cancer; 1996 Jun; 73(11):1373-80. PubMed ID: 8645582
[TBL] [Abstract][Full Text] [Related]
15. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
Lau DH; Lewis AD; Ehsan MN; Sikic BI
Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
[TBL] [Abstract][Full Text] [Related]
16. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
Giaccone G; Gazdar AF; Beck H; Zunino F; Capranico G
Cancer Res; 1992 Apr; 52(7):1666-74. PubMed ID: 1312895
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.
Kishimoto S; Miyazawa K; Terakawa Y; Ashikari H; Ohtani A; Fukushima S; Takeuchi Y
Jpn J Cancer Res; 2000 Dec; 91(12):1326-32. PubMed ID: 11123433
[TBL] [Abstract][Full Text] [Related]
18. Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells.
de Tinguy-Moreaud E; Pourquier P; Montaudon D; Robert J
Anticancer Res; 1994; 14(1A):99-103. PubMed ID: 8166463
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase II in multiple drug resistance.
Hofmann GA; Mattern MR
Cytotechnology; 1993; 12(1-3):137-54. PubMed ID: 7765323
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
